Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Código QR

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Bekalu Amare Tesfaye, Selamawit Tesfamariam Gebrekirstos, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Muluken Altaye Ayza Tel +251-916707913 Email Mulealto1@gmail...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ayza MA, Zewdie KA, Tesfaye BA, Gebrekirstos ST, Berhe DF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	diabetes mellitus hypertension peroxisome proliferator-activated receptors telmisartan Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5e533ab8d45444739832511dd2413d0e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
por: Bodh I Jugdutt
Publicado: (2010)

PPAR research

Ultrasound Assisted a Peroxisome Proliferator-Activated Receptor (PPAR)γ Agonist-Loaded Nanoparticle-Microbubble Complex to Attenuate Renal Interstitial Fibrosis
por: Wei S, et al.
Publicado: (2020)

PPARα Modulation-Based Therapy in Central Nervous System Diseases
por: Deokho Lee, et al.
Publicado: (2021)

Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells
por: Shadi Esmaeili, et al.
Publicado: (2021)

Peroxisome Proliferator-Activated Receptors (PPARs) and Oxidative Stress in Physiological Conditions and in Cancer
por: Giuliana Muzio, et al.
Publicado: (2021)

CLINICAL EFFICIENCY AND SAFETY OF FENOFIBRATE, A PPARα AGONIST, IN THE PATIENTS WITH DIABETESASSOCIATED OSTEOARTHRITIS: A CROSS-OVER PILOT STUDY
por: V. S. Shirinsky, et al.
Publicado: (2017)

Effects Of PPARγ2 Pro12Ala Variant On Adipocyte Phenotype Dependent Of DHA
por: Wan R, et al.
Publicado: (2019)

Nutrición molecular, papel del sistema PPAR en el metabolismo lipídico y su importancia en obesidad y diabetes mellitus: regulation of lipid metabolism by peroxisome proliferator activated receptors (PPAR). Their relatioship to obesity and diabetes mellitus
por: Uauy D,Ricardo, et al.
Publicado: (2000)

Telmisartan is effective to ameliorate metabolic syndrome in rat model – a preclinical report
por: Cheng KC, et al.
Publicado: (2018)

Securidaca inappendiculata-Derived Xanthones Protected Joints from Degradation in Male Rats with Collagen-Induced Arthritis by Regulating PPAR-γ Signaling
por: Zuo J, et al.
Publicado: (2021)

STABILITY - INDICATING LC METHOD FOR THE SIMULTANEOUS DETERMINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE IN DOSAGE FORM
por: PATIL,KIRAN R, et al.
Publicado: (2012)

A VALIDATED DENSITOMETRIC METHOD FOR ANALYSIS OF TELMISARTAN AND ATORVASTATIN CALCIUM IN FIXED DOSE COMBINATION
por: PATIL,U. P, et al.
Publicado: (2010)

(+)-Dehydrovomifoliol Alleviates Oleic Acid-Induced Lipid Accumulation in HepG2 Cells via the PPARα–FGF21 Pathway
por: Yiyuan Xi, et al.
Publicado: (2021)

Telmisartan Loaded Nanofibers Enhance Re-Endothelialization and Inhibit Neointimal Hyperplasia
por: Chen-Hung Lee, et al.
Publicado: (2021)

Transdermal Delivery of Telmisartan: Formulation, in vitro, ex vivo, Iontophoretic Permeation Enhancement and Comparative Pharmacokinetic Study in Rats
por: Teaima M, et al.
Publicado: (2021)

Phospholipase A2 group IIA correlates with circulating high-density lipoprotein cholesterol and modulates cholesterol efflux possibly through regulation of PPAR-γ/LXR-α/ABCA1 in macrophages
por: Ling Liang, et al.
Publicado: (2021)

Gene Doping with Peroxisome-Proliferator-Activated Receptor Beta/Delta Agonists Alters Immunity but Exercise Training Mitigates the Detection of Effects in Blood Samples
por: Brigitte Sibille, et al.
Publicado: (2021)

Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats
por: Samsu N, et al.
Publicado: (2019)

Nuclear Receptors in Myocardial and Cerebral Ischemia—Mechanisms of Action and Therapeutic Strategies
por: Joanna Rzemieniec, et al.
Publicado: (2021)

Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation
por: Kaleigh Katzer, et al.
Publicado: (2021)

Stability-indicating RP-HPLC method development and validation for simultaneous estimation of telmisartan and rosuvastatin calcium in bulk and in tablet dosage form
por: Rameshwar Gholve, et al.
Publicado: (2021)

Effect of telmisartan, angiotensin‐converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs
por: Brittany L. Fowler, et al.
Publicado: (2021)

Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1)
por: Ling Chen, et al.
Publicado: (2021)

Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound
por: Zhijun He, et al.
Publicado: (2021)

Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation
por: Tojo A, et al.
Publicado: (2015)

Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus
por: Ivona Yanovna Yarek-Martynova, et al.
Publicado: (2010)

Asociación de la región microsatélite AGAT del gen receptor de mineralocorticoides con los niveles de actividad renina en hipertensos esenciales
por: Muñoz-Brauning,Carlos R, et al.
Publicado: (2005)

Actualización en el manejo clínico de la hipertensión hiporreninémica
por: Macchiavello,Stefano, et al.
Publicado: (2019)

Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus
por: Tafere GG, et al.
Publicado: (2020)

Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
por: Li-Song Zhang, et al.
Publicado: (2012)

Development of potency assays for a plasmid containing vascular endothelial growth factor 2
por: Huang,Li-chun, et al.
Publicado: (2010)

Improved Histoarchitectural Changes with Angiotensin Receptor Blockers in Early Testicular and Cauda Toxicity in Rats
por: Faddladdeen,Khadija Abduljalil, et al.
Publicado: (2019)

Decreased, Deformed, Defective—How HIV-1 Vpu Targets Peroxisomes
por: Kristina Hopfensperger, et al.
Publicado: (2020)

The HIV-1 Accessory Protein Vpu Downregulates Peroxisome Biogenesis
por: Zaikun Xu, et al.
Publicado: (2020)

Evaluation of the role of the Endoplasmic Reticulum-Golgi transit in the biogenesis of peroxisomal membrane proteins in wild type and peroxisome biogenesis mutant CHO cells
por: TORO,ANDRÉS, et al.
Publicado: (2007)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications
por: Wondafrash DZ, et al.
Publicado: (2020)

A Common 34C>G Variant at the Peroxisome Proliferator-Activated Receptor γ2- Gene in Chilean Women with Polycystic Ovary Syndrome and Controls
por: Guzmán,Neftalí, et al.
Publicado: (2007)

<named-content content-type="genus-species">Trypanosoma brucei</named-content> Pex13.2 Is an Accessory Peroxin That Functions in the Import of Peroxisome Targeting Sequence Type 2 Proteins and Localizes to Subdomains of the Glycosome
por: Logan P. Crowe, et al.
Publicado: (2020)